Last reviewed · How we verify

Akeso, Inc. — Portfolio Competitive Intelligence Brief

Akeso, Inc. (9926) pipeline: 0 marketed, 0 filed, 16 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9926 (HKEX) 0 marketed 0 filed 16 Phase 3 7 Phase 2 21 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo, docetaxel Placebo, docetaxel phase 3 Taxane; microtubule stabilizer Beta-tubulin Oncology
Durvalumab, Gemcitabine, Cisplatin Durvalumab, Gemcitabine, Cisplatin phase 3 PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin) PD-L1 (durvalumab); DNA (gemcitabine and cisplatin) Oncology
AK104(IV) AK104(IV) phase 3 Bispecific checkpoint inhibitor PD-1 and TIM-3 Oncology
AK104(SC) AK104(SC) phase 3 Bispecific antibody; PD-1/TIM-3 checkpoint inhibitor PD-1; TIM-3 Oncology
AK101 SC AK101 SC phase 3 Bispecific T cell engager (BiTE) CD3 and PSMA Oncology
AK101 AK101 phase 3 Bispecific T-cell engager (BiTE) CD3 / PSMA Oncology
AK112, Gemcitabine, Cisplatin AK112, Gemcitabine, Cisplatin phase 3 Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy PD-1 and LAG-3 Oncology
AK102 AK102 phase 3 Bispecific checkpoint inhibitor PD-1 and CTLA-4 Oncology
AK112, Carboplatin, Paxlitaxel AK112, Carboplatin, Paxlitaxel phase 3 Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination PD-1 and LAG-3 Oncology
Ivonescimab, docetaxel Ivonescimab, docetaxel phase 3 PD-L1/CTLA-4 bispecific antibody + taxane chemotherapy PD-L1, CTLA-4 (ivonescimab); β-tubulin (docetaxel) Oncology
AK117 in combination with AK112 AK117 in combination with AK112 phase 3 Bispecific monoclonal antibody PD-1/LAG-3 (AK117) and PD-L1/TIM-3 (AK112) Oncology
AK111 AK111 phase 3 Bispecific T-cell engager (BiTE) CD3 and EGFR Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bio-Thera Solutions · 5 shared drug classes
  2. Jiangsu HengRui Medicine Co., Ltd. · 4 shared drug classes
  3. Sun Yat-sen University · 4 shared drug classes
  4. Sanofi · 3 shared drug classes
  5. Pfizer · 3 shared drug classes
  6. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 shared drug classes
  7. Amgen · 3 shared drug classes
  8. Merck Sharp & Dohme LLC · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Akeso, Inc.:

Cite this brief

Drug Landscape (2026). Akeso, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/akeso. Accessed 2026-05-14.

Related